MDNA11
Asset
Engineered IL-2 superkine designed to selectively activate effector T and NK cells
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- IL2RB
- 4
- Indications
- 0
- Trials
- 1
- Developer
Indications
4Advanced and metastatic gastrointestinal cancer
Phase 2, globenewswire.com, 5 Oct 2026
Endometrial cancer
Phase 2, globenewswire.com, 5 Oct 2026
Gastrointestinal cancer
Phase 2, globenewswire.com, 5 Oct 2026
1 more
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.